for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mersana Therapeutics Inc

MRSN.OQ

Latest Trade

1.75USD

Change

-0.09(-4.89%)

Volume

104,066

Today's Range

1.72

 - 

1.86

52 Week Range

1.72

 - 

12.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.84
Open
1.83
Volume
104,066
3M AVG Volume
4.99
Today's High
1.86
Today's Low
1.72
52 Week High
12.40
52 Week Low
1.72
Shares Out (MIL)
47.81
Market Cap (MIL)
87.97
Forward P/E
-2.94
Dividend (Yield %)
--

Next Event

Mersana Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Mersana Therapeutics Q2 Loss Per Share $0.36

Mersana Therapeutics Reports Q1 EPS Of $0.72

Sarissa Capital Management LP Reports 7.9% Passive Stake In Mersana Therapeutics Inc As Of March 1, 2019 - SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mersana Therapeutics Inc

Mersana Therapeutics, Inc. is a biotechnology company. The Company is focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies.

Industry

Biotechnology & Drugs

Contact Info

840 Memorial Dr

+1.617.4980020

http://www.mersana.com/

Executive Leadership

David M. Mott

Independent Chairman of the Board

Anna Protopapas

President, Chief Executive Officer, Director

Brian DeSchuytner

Senior Vice President - Finance and Product Strategy

Michael Kaufman

Senior Vice President - Chemistry, Manufacturing and Controls

Timothy B. Lowinger

Chief Scientific Officer

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-3.220

2018

-2.790

2019(E)

-0.627
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.97
Price To Book (MRQ)
0.81
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
4.80
LT Debt To Equity (MRQ)
4.73
Return on Investment (TTM)
-36.40
Return on Equity (TTM)
-28.15

Latest News

Mersana's cancer drug trial put on hold by FDA; shares halted

Mersana Therapeutics said on Thursday an early stage trial testing its lead cancer drug has been put on partial hold by the U.S. Food and Drug Administration after a patient's death was possibly linked to the treatment.

Mersana Therapeutics cancer drug trial on partial hold by FDA

Mersana Therapeutics said on Thursday its early-stage trial for its cancer drug has been put on partial hold by the U.S. health regulator after a patient's death was possibly related to the treatment.

BRIEF-Mersana Therapeutics Reports Q1 Loss Per Share $0.54

* MERSANA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61

* MERSANA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

BRIEF-Mersana Appoints David Spellman As Chief Financial Officer

* MERSANA APPOINTS DAVID A. SPELLMAN AS CHIEF FINANCIAL OFFICER

BRIEF-Mersana Announces First Patient Dosed With XMT-1536 In Phase 1 Study In Patients With NaPi2b-Expressing Tumors

* MERSANA ANNOUNCES FIRST PATIENT DOSED WITH XMT-1536 IN PHASE 1 STUDY IN PATIENTS WITH NAPI2B-EXPRESSING TUMORS Source text for Eikon: Further company coverage:

BRIEF-Mersana announces third quarter loss of $0.35 per share

* Mersana announces third quarter 2017 financial results and provides business updates

BRIEF-Mersana announces FDA clearance of IND application for XMT-1536

* Mersana announces FDA clearance of IND application for XMT-1536, a first-in-class antibody drug conjugate targeting NaPi2b

BRIEF-Mersana Therapeutics increases size of board and appoints Lawrence Alleva as class III director

* Mersana Therapeutics Inc - Increased size of the board from six to seven directors and appointed Lawrence M. Alleva to serve as a class III director Source text: (http://bit.ly/2j4r2t3) Further company coverage:

BRIEF-Mersana Q2 loss per share $6.33

* Mersana announces second quarter 2017 financial results and provides business updates

BRIEF-Mersana Therapeutics says Pfizer reports 9.8 percent passive stake in Mersana as of July 3 - SEC Filing

* Pfizer Inc. reports 9.8 percent passive stake in Mersana Therapeutics Inc as of July 3 - sec filing Source text for Eikon: Further company coverage:

BRIEF-Rock Springs Capital Management reports 6.8 pct passive stake in Mersana Therapeutics as of June 28, 2017

* Rock Springs Capital Management LP reports a 6.8 percent passive stake in Mersana Therapeutics Inc as of June 28, 2017 - sec filing Source text (http://bit.ly/2uTwTCc) Further company coverage:

BRIEF-Mersana Therapeutics announces pricing of initial public offering

* Mersana Therapeutics announces pricing of initial public offering

BRIEF-Mersana Therapeutics sees IPO of 5 mln shares priced between $14 and $16

* Mersana Therapeutics Inc sees IPO of 5 million shares priced between between $14.00 and $16.00 - SEC filing Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up